You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. IGF OT IGF HIGH CONTENT SCREENING FOR HUMAN PRIMARY PANCREATIC CELL TYPE SPECIFIC TOXICANTS

    SBC: Zen-Bio, Inc.            Topic: NIDA

    Not Available

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. CHEMOENZYMATIC SYNTHESIS OF HEPARAN SULFATE OLIGOSACCHARIDES

    SBC: GLYCAN THERAPEUTICS CORPORATION            Topic: NCI

    The goal of this contract is to synthesize a heparan sulfate HS library consisting of structurally homogeneous oligosaccharides in response to an SBIR contract call from NCl Chemically Defined Glycan Libraries The Contractor specializes in the synthesis of structurally diverse HS oligosaccharides The Contractor has built an innovative chemoenzymatic method for Glycan synthesis Polymeri ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  3. IGF OT IGF Fluorescent Nanodiamonds for In Vitro and In Vivo Biological Imaging SBIR Topic Phase II

    SBC: ADAMAS NANOTECHNOLOGIES INC            Topic: NHLBI

    Not Available

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  4. IGF OT IGF ARISE AN ONLINE RELAPSE PREVENTION TOOL FOR SUBSTANCE ABUSERS N DA POP SEPTEMBER SEPTEMBER SUPPLEMENTAL W IN SCOPE

    SBC: 3-C Institute for Social Development, Inc.            Topic: NIDA

    Not Available

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Contraceptive testing for semen availability in male monkeys

    SBC: EPPIN PHARMA INC            Topic: NICHD

    DESCRIPTION provided by applicant The global contraceptives market was valued at $ billion in and is expected to grow at a CAGR of from to to reach an estimated value of $ billion in An important high impact driver of this market is the prevalence of unintended pregnancies In the US there are million unintended pregnancies annually through inconsistent or ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Developing therapeutic inhibitors of CIB1 for breast cancer

    SBC: Reveris Therapeutics            Topic: 102

    DESCRIPTIONprovided by applicantBreast cancer is the most common malignancy in women living in the USwith more thannew cases diagnosed each yearand an estimatedwomen dying from the disease inGreater thanof these diagnoses are classified as triple negative breast cancerTNBCwhich is considered among the most aggressive breast cancer sub typeswith the worst prognosisTNBC is difficult to treat because ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. New Class of Bright, Sharp, Tunable Red/Far-Red Fluorophores for Flow Cytometry

    SBC: Nirvana Sciences, Inc.            Topic: NIBIB

    DESCRIPTION provided by applicant Polychromatic flow cytometry FC is one of the most powerful analytical techniques used in immunology basic research and clinical medicine In basic research FC is a primary tool for understanding disease development at the cellular and subcellular levels In the rapidly developing field of immunotherapy FC is an indispensable tool for monitoring the effec ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a novel method for inhibiting diabetic retinopathy

    SBC: CMP Tarnhelm Partners            Topic: N

    DESCRIPTION provided by applicant The long term objective of this project study is to develop a monoclonal antibody that inhibits the progression of diabetic retinopathy Insulin like growth factor I IGF I has been implicated in both endothelial dysfunction as well as the proliferative phase of the disease but IGF I concentrations in retina are not increased During hyperglycemia IGF I activa ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Implantation of Bioengineered Intrinsically Innervated Internal Anal Sphincter (BioSphincter) to Treat Fecal Incontinence

    SBC: CELLF-BIO LLC            Topic: 300

    DESCRIPTION provided by applicant We propose to bring to market a novel regenerative medicine based therapy for fecal incontinence FI FI is the recurrent uncontrolled passage of fecal material The Internal Anal Sphincter IAS is responsible for maintaining anorectal continence Function of the IAS is dependent upon the neuromuscular integrity of both the smooth muscle and the intrinsic en ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Delivery of peptides for inducing voiding associated with neurological retention

    SBC: Dignify Therapeutics LLC            Topic: 102

    DESCRIPTION provided by applicant Neurological conditions such as multiple sclerosis Parkinsonandapos s disease dementia spina bifida diabetes stroke and spinal cord injury SCI can result in loss of voluntary control over bladder and bowel function often producing both incontinence and retention of urine and stools in the same patient This has a profound impact on the mental and phy ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government